Compare GBX & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBX | ARDX |
|---|---|---|
| Founded | 1974 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2014 |
| Metric | GBX | ARDX |
|---|---|---|
| Price | $46.46 | $5.99 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $50.67 | $10.65 |
| AVG Volume (30 Days) | 334.5K | ★ 2.8M |
| Earning Date | 01-08-2026 | 10-30-2025 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 27.96 | N/A |
| EPS | ★ 6.35 | N/A |
| Revenue | ★ $3,240,200,000.00 | $398,234,000.00 |
| Revenue This Year | N/A | $22.71 |
| Revenue Next Year | N/A | $27.81 |
| P/E Ratio | $7.33 | ★ N/A |
| Revenue Growth | N/A | ★ 58.12 |
| 52 Week Low | $37.77 | $3.21 |
| 52 Week High | $71.06 | $6.78 |
| Indicator | GBX | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 54.95 |
| Support Level | $46.02 | $5.63 |
| Resistance Level | $47.03 | $5.90 |
| Average True Range (ATR) | 1.02 | 0.26 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 41.90 | 46.15 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.